Anthropic's life-science work in 2026 has three parts: enterprise agreements with large drugmakers, research partnerships with biotech companies, and drug discovery programmes of its own. On October 27, 2026 it named six research partners and said it had acquired Mithril Medicine, a one-person company working on two rare forms of muscular dystrophy. No financial terms have been published for any of these arrangements. As of November 13, 2026, nearly all of the work is preclinical.
Timeline
| Date | Event |
|---|---|
| October 2025 | Claude for Life Sciences launched, with connectors to lab and literature tools |
| January 11, 2026 | Anthropic's healthcare and life sciences update names Novo Nordisk, Sanofi, Genmab, Schrödinger, Veeva, Flatiron Health and Edison Scientific as users, and adds connectors including ClinicalTrials.gov, ChEMBL, Open Targets and Medidata |
| May 20, 2026 | Bristol Myers Squibb announces a strategic agreement to deploy Claude to more than 30,000 employees |
| June 30, 2026 | Claude Science released in beta. Anthropic says it will start its own drug discovery programmes for neglected diseases |
| September 16, 2026 | Novo Nordisk announces it will use Claude models and Claude Science in R&D |
| October 27, 2026 | Anthropic publishes early results from six research partners and discloses the Mithril Medicine acquisition |
The Six Research Partners Named on October 27
The figures below are Anthropic's and its partners' own, from laboratory or document work. None is a clinical result.
| Partner | Stage of work | What Anthropic reported |
|---|---|---|
| Generate Biomedicines | Design of a cell therapy component | Six scientists used Claude Code to propose shorter designs for part of a CAR T-cell therapy. One design was about 70% shorter than the standard version |
| Divergence Labs | Finding starting molecules | About 35,000 antibody designs generated in roughly a month for a food allergy project |
| BigHat Biosciences | Improving lead molecules | About 1,010 variants of two antibody fragments made and tested in about 10 weeks |
| Enveda | Manufacturing and regulatory documents | On 1,061 pages of records, human review time fell 89%, from over 25 hours to under 3 |
| The Column Group | Company creation | Building a new company, Pleiades, designed to run drug programmes with a small team using Claude |
| Bristol Myers Squibb | Clinical trial planning | Using Claude to assess plans for an early-stage drug. Wider use is planned for 2027 |
Anthropic's post says the research is early and mostly preclinical, and that most of the drugs involved have not been tested in people.
Enterprise Agreements
- Bristol Myers Squibb, May 20, 2026. Claude across research, clinical development, manufacturing, commercial and corporate functions, reaching more than 30,000 employees. Engineering teams use Claude Code. The company said it would evaluate Claude as an agent layer in drug development workflows. Terms were not disclosed.
- Novo Nordisk, September 16, 2026. Euronews reported that the company will use Anthropic's models in R&D and test Claude Science. Terms were not disclosed. Novo Nordisk also has an agreement with OpenAI from April, and the reports do not say either is exclusive.
- Sanofi. Anthropic's January 2026 post says most Sanofi employees use Claude daily.
Anthropic's Own Drug Programmes
On June 30, 2026, at a virtual event, Anthropic said it would run its own drug discovery programmes for neglected diseases, meaning conditions that drug companies tend not to pursue for commercial reasons. It said the work would be early and preclinical, and that doing it first-hand would help it build better tools for the industry.
The October 27 post gave the first specifics:
- Anthropic acquired Mithril Medicine, a one-person company developing treatments for two rare forms of muscular dystrophy. The price was not disclosed.
- Its founder, Cody Tranbarger, used Claude to organise contracts, logistics and experiments with 11 outside laboratories, and now works at Anthropic.
- One programme went from an idea to mouse studies in under 18 months.
- If the candidates continue to hold up, a drug could be ready to start human trials as soon as late 2028. That is a conditional statement, not a schedule.
No Anthropic compound is in a clinical trial. For compounds from other AI companies that are, see AI-designed drugs in clinical trials.
Claude Science and Access Programmes
Claude Science is a workbench application for researchers, not a new model. Press coverage describes more than 60 built-in skills and connectors for genomics, proteomics, structural biology and cheminformatics, and says it runs on Linux, macOS or a remote machine. It is in beta for paid Claude plans, according to launch coverage. Anthropic also offers Claude credits to life scientists, an open call for guest investigators, and a Life Sciences Verification Program that gives trusted organisations more permissive safeguards for legitimate biological research. A side-by-side with OpenAI's and Isomorphic's efforts is at Claude Science vs GPT-Rosalind vs Isomorphic Labs.
Methodology
Partner results, the Mithril acquisition and the 2028 statement come from Anthropic's October 27, 2026 post. January users and connectors come from its January 11, 2026 post. The Claude Science launch and the neglected-disease statement come from The Decoder and Pharmaceutical Technology, because we could not open an Anthropic launch page. The Bristol Myers Squibb agreement is from Fierce Biotech and other trade coverage of the company release, and the Novo Nordisk agreement from Euronews. Presenc AI has not tested Claude Science. Status as of November 13, 2026.